|Fetal haemopoiesis marking low-grade urinary bladder cancer.|
|Jump to Full Text|
|PMID: 22735903 Owner: NLM Status: MEDLINE|
|BACKGROUND: The immunohistochemical features of fetal haemoglobin cells and their distribution patterns in solid tumours, such as colorectal cancer and blastomas, suggest that fetal haemopoiesis may take place in these tumour tissues. These locally highly concentrated fetal haemoglobin (HbF) cells may promote tumour growth by providing a more efficient oxygen supply.
METHODS AND RESULTS: Biomarkers of HbF were checked in transitional cell carcinoma (TCC) of the urinary bladder, assessing this as a new parameter for disease management. Fetal haemoglobin was immunohistochemically examined in tumours from 60 patients with TCC of the bladder. Fetal haemoglobin erythrocytes and erythroblasts were mainly clonally distributed in proliferating blood vessels and not mixed with normal haemoglobin erythrocytes. The proportion of such HbF blood vessels could reach more than half of the total number of vessels. There were often many HbF erythroblasts distributed in one-cell or two-cell capillaries and present as 5-15% of cells in multi-cell vessels. This suggests a local proliferation of HbF-cell progenitors. Fetal haemoglobin cells were prominently marking lower grades of tumours, as 76% (n=21) of the patients with G1pTa were HbF+, whereas only 6.7% (n=30) of the patients with G3pT1-pT2a were HbF+.
CONCLUSION: Our results suggest that HbF, besides being a potential new marker for early tumour detection, might be an essential factor of early tumour development, as in fetal life. Inhibiting HbF upregulation may provide a therapeutic target for the inhibition of tumour growth.
|M Wolk; J E Martin|
Related Documents :
|3115993 - Effects of denervation induced by 6-hydroxydopamine on cell nucleus activity of arteria...
10775483 - Expression of plasma membrane calcium atpases in phenotypically distinct canine vascula...
3820273 - Adherence of fusobacterium necrophorum to bovine ruminal cells.
|Type: Journal Article Date: 2012-06-26|
|Title: British journal of cancer Volume: 107 ISSN: 1532-1827 ISO Abbreviation: Br. J. Cancer Publication Date: 2012 Jul|
|Created Date: 2012-07-25 Completed Date: 2013-01-08 Revised Date: 2013-07-24|
Medline Journal Info:
|Nlm Unique ID: 0370635 Medline TA: Br J Cancer Country: England|
|Languages: eng Pagination: 477-81 Citation Subset: IM|
|© 2012 Cancer Research UK|
|Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Core Pathology Facility, The Royal London Hospital, 80 Newark Street, London E1 2ES, UK. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Blood Vessels / metabolism, pathology
Carcinoma, Transitional Cell / blood, metabolism, pathology*
Cell Transformation, Neoplastic / metabolism, pathology
Erythroblasts / metabolism, pathology
Erythrocytes / metabolism, pathology
Fetal Hemoglobin / metabolism*
Tumor Markers, Biological / metabolism*
Urinary Bladder Neoplasms / blood, metabolism, pathology*
|0/Tumor Markers, Biological; 9034-63-3/Fetal Hemoglobin|
Journal ID (nlm-ta): Br J Cancer
Journal ID (iso-abbrev): Br. J. Cancer
Publisher: Nature Publishing Group
Copyright © 2012 Cancer Research UK
Received Day: 07 Month: 03 Year: 2012
Revision Received Day: 16 Month: 05 Year: 2012
Accepted Day: 20 Month: 05 Year: 2012
Print publication date: Day: 24 Month: 07 Year: 2012
Electronic publication date: Day: 26 Month: 06 Year: 2012
Volume: 107 Issue: 3
First Page: 477 Last Page: 481
PubMed Id: 22735903
Publisher Item Identifier: bjc2012268
|Fetal haemopoiesis marking low-grade urinary bladder cancer Alternate Title:Fetal haemoglobin marking urinary bladder cancer|
|J E Martin1|
1Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Core Pathology Facility, The Royal London Hospital, 80 Newark Street, London E1 2ES, UK
Systemic, high, whole blood concentration of fetal haemoglobin (HbF) is a well-established feature of haematological and solid tumours (Sheridan et al, 1976; Wolk et al, 1988, Rautonen and Mari, 1990). However, there is evidence suggesting local proliferation of HbF cells in tumour tissues. This was serologically demonstrated in lymphoma, ovarian cancer, brain cancer and other cancers by a high plasma HbF concentration independent of the whole blood concentration (Wolk et al, 1999). The same was also immunohistochemically shown in colorectal tumours (Wolk et al, 2006), as well as in blastomas (Wolk et al, 2007), by high concentrations of HbF erythroid cells, distributed as separated clusters rather than mixed with the normal erythrocytes, in blood vessels. To investigate this trait further, we decided to examine HbF in transitional cell carcinoma (TCC) of the urinary bladder in relation to the grade and stage of the disease. Although new markers for TCC have been evaluated during the past decade in order to improve management, they have not replaced traditional methods of urine cytology, although this is limited by its low sensitivity (Mukhtar and Perry, 2011). The most promising of these new techniques involve specific protein immunoassay (Stoeber et al, 2002) or molecular (Miyake et al, 2010) and genomic (Wang et al, 2009) biomarkers and require complicated techniques, which are not yet compatible with clinical practice. Fetal haemoglobin, however, if proved a suitable marker for TCC, might be easily evaluated serologically in blood or urine and by immunohistochemistry in tumour biopsies.
The study was conducted in the Blizard Institute, Core Pathology Group, Barts and The London School of Medicine and Dentistry, using archival and stored materials. The study was approved by the Research Ethics Committee of the East London and City Health Authority. Histopathological specimens from bladder TCC patients were selected from the archive of the Department of Histopathology, the Royal London Hospital. The grade and stage of tumours were derived from records and reviewed for the blocks studied. The study comprised 60 patients, of whom 9 were women. The patients' age range was 43–97 years (median=76); the grade distribution was as follows: 21 patients=G1, 8=G2, 30=G3 and 1=in situ TCC. Five controls of non-malignant bladder tissues were examined in parallel. No chemotherapy treatment was given at least 6 months preceding excision of the specimens.
We used the peroxidase-labelled avidin–biotin method (Hsu and Raine, 1984). Formalin-fixed, paraffin wax-embedded cross-sections were cut at 3 μm, dewaxed, and then blocked for endogeneous peroxidase with 3% H2O2 in water for 15 min, and washed for 5 min in water and then for 5 min in TBS (0.05 tris buffered saline) wash buffer (Dako A/S, Glostrup, Denmark). The following incubation steps were used: (1) blocking with normal rabbit serum, diluted 1 : 5 for 30 min; (2) incubation with primary antibody, that is, affinity-purified sheep anti-human HbF (Abcam, Cambridge, UK), diluted 1 : 400 for 60 min; (3) incubation with secondary antibody, i.e., biotinylated rabbit anti-sheep IgG (Vector Laboratories, Burlingame, CA, USA), diluted 1 : 150 for 30 min; (4) incubation with ready-to-use streptavidin–biotin complex (RTU Vectastain Elite ABC, Vector Laboratories) for 30 min; and (5) incubation with DAB solution (chromogen; DAB kit, Vector Laboratories) for 4 min. The sections were then washed for 5 min in running water, automatically counterstained with Gill's haematoxylin, blue-differentiated, dehydrated and mounted. Between steps (1) through (4), the sections were washed in TBS wash buffer for 5 min. Staining was confirmed by two controls, where in step (2) we used the same anti-human HbF absorbed with HbF as negative control and human HbF absorbed with normal haemoglobin (HbA) as positive control. Fetal haemoglobin and HbA were prepared from the corresponding red cell lysates, insolubilised by the aid of gluteraldehyde (Wolk and Kieselstein, 1983) and then two volumes of anti-HbF were shaken at room temperature for 12 h, with one volume of either of those absorbents. The supernatants were then saved for control staining in place of the primary antibody.
The criteria for positivity were as follows: (1) proliferating fine vessels with 100% HbF blood cells, distributed throughout the section; and (2) larger blood vessels with >50% HbF blood cells. Negative cases were sections without HbF blood cells, or with occasional <1%–5% HbF blood cells. As shown in Table 1, the percentage of HbF+ tumours was much higher in the noninvasive, low-grade G1 group (76%) than in the high-grade G3 group (6.7% ), whereas in the G2 group it was intermediate (50%).
Fetal haemoglobin blood cell distribution is given in Table 2, in which a distinction is made between three kinds of blood vessels: (1) with adult haemoglobin (HbA) blood cells, (2) with a mixed population, including 10–40% HbF cells and (3) with predominantly HbF blood cells, >50% HbF cells. As shown in this table, the percentages of HbF+ vessels were, in most cases, over 50% (Figures 1A–C). Proliferation of HbF cells was indicated by nucleated (erythroblast and proerythroblast) cells filling one- or two-cell capillaries (Figure 2) or mixed with the HbF erythrocytes (Figures 1, 3 and 4). As shown in Table 2, the HbF blood vessels were distributed within the tumour (Figures 3 and 4) and in the lamina propria (Figures 1A–C), where the most intensive proliferation of fine blood vessels was noted. The HbF and the non-HbF blood vessels were distributed in separated areas throughout the sections. Proliferation of blood vessels with non-HbF blood cells, although present in low-grade G1 patients, was most prominent between the invasive tumour cells of high-grade G3 patients (Figure 5), where no vessels with HbF cells were observed.
Five control biopsies from patients suspected of cancer, which were normal, were all without HbF blood cells.
Local proliferation of HbF blood cell progenitors within the tumour is likely to be the main mechanism responsible for the high concentration of HbF blood cells. The histological picture shows multiple nucleated HbF cells (Figure 1, Table 2), sometimes filling up small capillaries (Figure 2), and proliferative patterns of fine to bigger blood vessels, filled predominantly with HbF cells apart from the normal Hb vasculature, probably due to the local fetal haemopoiesis in the tumour tissue. The extremely high concentration of blood vessels with HbF cells throughout TCC bladder tissue makes the bladder erythroid blood supply predominantly a fetal one. Owing to its high oxygen affinity, HbF might have a particular role in supporting cancer growth by providing an efficient oxygen delivery to the cells, as it does in fetal tissues during gestation (Carlson, 1988; Manca and Masala, 2008). Fetal haemoglobin (HbF) gene upregulation might thus be an important factor in supporting low-grade tumours, and it is possible that its inhibition may help to arrest the malignant process at an early stage. This is relevant to therapeutic strategies for tumours, aimed at angiogenesis, which is an important strategy in cancer therapy (Wu et al, 2008; Goel et al, 2011). We therefore suggest that the reduction of HbF cells inside tumour vasculature, along with inhibiting proliferation of the unique endothelial cells of the tumour, might be a useful approach.
Despite many studies having been conducted, the molecular mechanism of HbF regulation is not completely understood. However, in the silencing of γ-genes expression in normal adults, there is thought to be a fundamental role of DNA methylation (Lavelle, 2004; Saunthararajah et al, 2004; Sankaran, 2011). Consequent to methylation, there is induction of histone deacetylation of the chromatin, causing a closed chromatin configuration around the methylated sequences, which maintain silencing of those genes (Lavelle, 2004). Methods for restoring histone deacetylation might be useful in downregulation of HbF and reduction of HbF cell concentration in tumour tissues to normal levels. These might include reactivation of the enzymes DNA methyl transferase (DNMT) and histone de-acetylase (HDAC) in those erythroid cells progenitors, as inhibitors of these enzymes are used to upregulate HbF, therapeutically (Saunthararajah et al, 2004) for DNMT or experimentally (Witt et al, 2003) for HDAC. Reactivation of HbF has been shown to be mediated by certain signalling mechanisms that activate γ-globin genes via upregulation of transcription factors. These signalling mechanisms include activation of receptor tyrosine kinase CD117 (c-kit) on the surface of erythroid progenitor cells by stem cell factor (c-kit ligand), which has a key role in HbF reactivation in adult life (Wojda et al, 2003; Bhnu et al, 2004; Gabbianelli et al, 2010). Inhibitors of that signalling pathway, such as PD98059 (Bhnu et al, 2004), might be used to reduce the concentration of erythroid HbF cells where they may support cancer growth. Another approach to downregulation of HbF was shown in leukaemia cell lines, in which the concentration of HbF decreased to 15–5% of the control upon inhibition of the P-glycoprotein drug efflux pump (P-gp) (Fyrberg et al, 2011), indicating a link between P-gp and the induction of HbF.
The high incidence of blood vessels with predominant HbF erythroid cells in non-invasive low-grade tumours of the bladder suggests HbF as a potential prognostic marker in early stages of the disease. The use of HbF as such a marker requires larger-scale observation in TCC, as well as in other solid tumours. Evaluation of bladder HbF could be facilitated by measuring its concentration in plasma or urine, in order to avoid invasive procedures. We have previously shown that HbF is a potential systemic blood marker in these patients, as all 10 patients who were serologically examined had elevated concentrations of HbF in the blood (Wolk et al, 1988, 1991). It will be important to scrutinise the incidence and biological behaviour of a range of tumours, including bladder tumours, in light of the increasing use of drugs to induce HbF therapeutically.
This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
We acknowledge the technical assistance of C Evagora, P levey, R Carrol and M Child from Queen Mary University of London ICMS/Pathology Group, The Royal London Hospital.
The authors declare no conflict of interest.
|Bhnu NV,Trice TA,Lee YT,Miller JL. Year: 2004A signaling mechanism for growth-related expression of fetal hemoglobinBlood1031929193314592835|
|Carlson BM. Year: 1988The development of the circulatory systemPatten's Foundations of EmbryologyDolinger E, Maisel J (eds). pp594McGraw-Hill: New York|
|Fyrberg A,Peterson C,Kagedal B,Lotfi K. Year: 2011Induction of fetal hemoglobin and ABCB1 gene exspression in 9-β-D-arabinofuranosylguanine-resistant MOLT-4 cellsCancer Chemother Pharmacol6858359121110023|
|Gabbianelli M,Testa U,Morsilli O,Pelosi E,Saulle E,Petrucci E,Casteli G,Giovinazzi S,Mariani G,Fiori ME,Bonanno G,Massa A,Corce CM,Fontana L,Peschele C. Year: 2010Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complexHaematologica951253126020305142|
|Goel S,Duda DG,Xu L,Munn LL,Boucher Y,Fukumura D,Jain RK. Year: 2011Normalization of the vasculature for treatment of cancer and other diseasesPhysiol Rev91071112121742796|
|Hsu Sb,Raine L. Year: 1984The use of avidin-biotin-peroxidase complex (ABC) in diagnostic and research pathologyAdvances in ImmunochemistryDelellis Ra (ed). pp3142Mason: New York|
|Lavelle DE. Year: 2004The molecular mechanism of fetal hemoglobin reactivationSemin Hematol41(4, suppl 631015534851|
|Manca L,Masala B. Year: 2008Disorder of synthesis of human fetal hemoglobinIUBMB Life609411118379999|
|Mukhtar S,Perry MJA. Year: 2011Future prospects for bladder cancer biomarkersBrit J Urol Int10813361345|
|Miyake M,Sugano K,Sugino H,Imai K,Mutsumoto E,Maeda K,Fukozono S,Ichikawa H,Kawashima K,Hirabayashi K,KJodama T,Fujimoto H,Kakizoe T,Kanai Y,Fujimoto K,Hirao Y. Year: 2010Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancerCancer Sci10125025819843069|
|Rautonen J,Mari AS. Year: 1990Initial blood fetal hemoglobin concentration is elevated and is associated with prognosis in children with acute lymphoid or myeloid leukemiaBlut6117201696840|
|Sankaran VG. Year: 2011Targeted therapeutic strategies for fetal hemoglobin inductionHeamatol Am Soc Heamatol Educ Program2011459465|
|Saunthararajah Y,Lavelle D,DeSimone J. Year: 2004DNA hypo-methylation agents and sickle cell diseaseBrit J Haematol12662963615327513|
|Sheridan BL,Weatherhall DJ,Clegg JB,Prichard J,Wood WG,Challender ST,DUrrant IJ,McWhirter WR,Ali M,Partridge JW,Thompson EN. Year: 1976The patterns of fetal haemoglobin production in leukaemiaBrit J Haematol32487506816370|
|Stoeber K,Swinn R,Prevost AT,de Clive-Lowe P,Halsall I,Dilworth SM,Marr J,Turner WH,Bullock N,Doble A,Hales CN,Williams GH. Year: 2002Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sedimentsJ Natl Cancer Inst941071107912122098|
|Wang R,Morris DS,Tonlis SA,Lonigro RJ,Tsodikov A,Mehra R,Giorando TJ,Kunjo LP,Lee CT,Weizer AZ,Chinaian AM. Year: 2009Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancerCancer Res693810381819383904|
|Witt O,Monkemeyer S,Roenndahl G,Erdlenbruch B,Reinhardt D,Kanbach K,Pekrun A. Year: 2003Induction of fetal hemogloboin expression by the histone deacetylase inhibitor ampicinBlood1012001200712393499|
|Wojda U,Leigh KR,Njoroge JM,Jackson KA,Natarajan B,Stitely M,Miller JL. Year: 2003Fetal hemoglobin modulation during human erythropoiesis: stem cell factor has “late” effects related to the expression pattern of CD117Blood10149249712393703|
|Wolk M,Kieselstein M. Year: 1983Graded hemagglutination inhibition for quantification of human fetal hemoglobinClin Chem29137213756190589|
|Wolk M,Kiesekstein M,Brufman G. Year: 1988Evaluation of fetal hemoglobin in various malignancies with reference to the patients' ageTumor Biol995100|
|Wolk M,Kieselstein M,Ben-Dor CG,Brufman G. Year: 1991Fetal Hemoglobin screening in whole blood and in plasma of cancer patientsTumor Biol124551|
|Wolk M,Newland AC,Dela Salle B,Peleg M,Brufman G. Year: 1999Refinement of plasma fetal hemoglobin (HbF) measurements, as related to whole blood HbF, in cancer patientsJ Tumor Marker Oncol14115124|
|Wolk M,Martin JE,Reinus C. Year: 2006Development of fetal haemoglobin-blood cells (F cells) within colorectal tumour tissuesJ Clin Pathol5959860216469830|
|Wolk M,Martin JE,Nowicki M. Year: 2007Foetal haemoglobin-blood cells (F-cells) as a feature of embryonic tumours (blastemas)Brit J Cancer9741241917595660|
|Wu H-C,Huang C-T,Chang D-K. Year: 2008Anti-angiogenic therapeutic drugs for treatment of human cancerJ Cancer Mol43745|
Keywords: HbF, fetal haemoglobin, bladder cancer, fetal haemopoiesis.
Previous Document: Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients.
Next Document: Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck c...